ORIGINAL RESEARCH

Association between Adherence to Guideline-Recommended Preventive Medications and In-Hospital Mortality among Non-Reperfused ST-Elevation Myocardial Infarction Patients Admitted to a Tertiary Care Academic Center in a Developing Country

Sylvi Irawati1,2,3, Surya Dharma4, Katja Taxis1, Thang Nguyen5, Nunung Nursyarofah6, Bob Wilffert1,7 and Eelko Hak1

1 University of Groningen, Groningen Research Institute of Pharmacy, PharmacoTherapy, Epidemiology and -Economics, Groningen, NL
2 Center for Medicines Information and Pharmaceutical Care, Faculty of Pharmacy, Universitas Surabaya, Surabaya, ID
3 Department of Clinical and Community Pharmacy, Faculty of Pharmacy, Universitas Surabaya, Surabaya, ID
4 Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Indonesia, Indonesian Cardiovascular Research Center, National Cardiovascular Center Harapan Kita, Jakarta, ID
5 Department of Pharmacology and Clinical Pharmacy, Can Tho University of Medicine and Pharmacy, Can Tho, VN
6 Indonesian Cardiovascular Research Center, National Cardiovascular Center Harapan Kita, Jakarta, ID
7 University of Groningen, Department of Clinical Pharmacy & Pharmacology, University Medical Center Groningen, Groningen, NL

Corresponding author: Sylvi Irawati (sylvirawati.2010@gmail.com)

Background and aims: Acute ST-elevation myocardial infarction (STEMI) is a potentially fatal presentation of coronary artery disease (CAD). Evidence of the impact of acute pharmacological interventions in non-reperfused STEMI patients on subsequent events is limited. We aimed to assess the association between adherence to guideline-recommended preventive medications and in-hospital mortality among this high-risk patient population.

Methods: We conducted a cohort study using data obtained from the Jakarta Acute Coronary Syndrome (JAC) Registry database from a tertiary care academic hospital in Indonesia. We included 1132 of 2694 patients with STEMI recorded between 1 January 2014 and 31 December 2016 who did not undergo acute reperfusion therapy. Adherence to guideline-recommended preventive medications was defined as the combined administration of aspirin, clopidogrel, anticoagulants and statins after hospital admission. The main outcome measure was in-hospital mortality.

Results: Overall, 778 of 1132 patients (69%) received the combination of preventive medications. The guideline non-adherent group had significantly more patients with earlier onset of STEMI, higher Killip class and thrombolysis in myocardial infarction (TIMI) score. After adjustments for measured characteristics using logistic regression modeling, exposure to the combination of preventive therapies was associated with a statistically significant lower risk for in-hospital mortality (adjusted odds ratio: 0.46, 95% confidence interval: 0.30–0.70).

Conclusions: Adherence to guideline-recommended preventive medications was associated with lower risk of in-hospital mortality in non-reperfused STEMI patients. The predictors of not receiving these medications need to be confirmed in future research.

Keywords: ST-elevation myocardial infarction; STEMI; no reperfusion therapy; guideline adherence; hospital mortality; Indonesia; developing countries
1. Introduction

Despite a 22% reduction in the median percentage of the age-standardized death rate due to ischemic heart disease (IHD) in the last two decades across populations worldwide, IHD is still the leading cause of death in the world [1]. IHD was the leading cause of years of life lost (YLL) in a fifth of the developing countries in 2015 [2–5]. This stresses the magnitude of the burden of IHD as YLL indicates a more appropriate measure of premature death. The YLL calculation considers the time lost associated with IHD death by multiplying the number of deaths at a certain age and the normative standard life expectancy of that age [4, 6]. Myocardial infarction (MI) with or without elevation of ST-segment is an acute and serious presentation of IHD [7–12]. The risks of death during and within six months after the index date of hospitalization are higher for patients with ST-segment elevation MI (STEMI) than with non-ST-segment elevation MI (NSTEMI) [13].

Acute reperfusion therapy, preferably timely primary percutaneous coronary intervention (pPCI) conducted maximally within 120 minutes since the first medical contact or STEMI diagnosis, is the best management for ischemic STEMI patients transferred from non-capable pPCI hospitals to capable pPCI hospitals [9, 11]. Despite continued attempts to implement this emergency care in patients with STEMI presenting at hospitals, up to more than 50% of these patients still did not receive acute reperfusion therapy [14, 15], especially in developing countries such as India [15], Indonesia [15–19], Philippines [15], and Vietnam [20]. Even in developed countries, around 20%–30% of patients with STEMI who were eligible for reperfusion still failed to receive this evidence-based intervention [21–23].

In developing countries like Indonesia, Malaysia, and the Philippines, late presentation at hospitals (defined as arrival >12 h from symptom onset) contributes to the low rate of pPCI utilisation. A targeted shorter time between the symptom onset and calling an ambulance or presenting at pPCI-capable hospitals was unachieved due to long distance to reach pPCI-capable centers and geographical barriers [15]. In Jakarta, traffic overcrowd, patient-related factors, pre-hospital diagnosis and treatment delay, lack of collaboration between hospital and physicians, and lack of ambulance organisation might cause the late presentation [16].

Inconsistencies exist in the evidence on the benefit of acute reperfusion therapy, primarily pPCI, over pharmacological therapy alone in patients with STEMI who present late [24–26]. International guidelines have not directly specified management on this type of STEMI patients [9, 11, 27]. It is suggested the same classes of medications such as dual antiplatelet therapy (DAPT), anticoagulants, and statins applied for reperfused patients are also applied for non-reperfused patients as one package [25]. However, this suggestion is based on trials in STEMI patients whom more than 50% of them were also reperfused by fibrinolytic agents [28] and in the era where other preventive medications, especially DAPT and statins, were not routinely used or not reported [27–30]. More over, populations understudied in these trials are at lower risk of in-hospital mortality compared to a ‘real-world’ setting. More than 70% of these populations presented with Killip class = 1 [28, 30] or without heart failure [29].

The effect size of using all classes of these preventive medications on in-hospital mortality in non-reperfused STEMI patients, especially in real-world developing countries where the risk is higher, is unclear. The objective of this study was to assess the association between adherence in prescribing a combination of guideline-recommended preventive medications and in-hospital mortality among non-reperfused STEMI patients admitted to a tertiary care academic hospital in Indonesia, a developing country.

2. Methods

2.1. Study design and setting

We performed a cohort study among non-reperfused STEMI patients prospectively registered in the Jakarta Acute Coronary Syndrome (JAC) Registry database from 1 January 2014 to 31 December 2016. The registry was set up in 2007 and is prospectively collecting and managing data on characteristics, management and outcomes of patients with ACS admitted to the emergency department (ED) of the National Cardiovascular Center Harapan Kita (NCCHK) which is the largest tertiary cardiac referral hospital in Jakarta, the capital of Indonesia. The hospital is JCI (Joint Committee International) accredited.

Data were collected prospectively and consecutively using a standardized registry form. In addition, all data were recorded in the database of the JAC registry after the patient was discharged. Data quality was maintained and verified regularly by the primary investigator of the registry (SD). The hospital provides a 24/7 cardiovascular service, including primary percutaneous coronary intervention (pPCI) and is hosting the regional STEMI network [17–19]. More details on the STEMI network characteristics in Jakarta was previously described [17]. In brief, patients with acute STEMI will be transferred to the nearest PCI center for primary PCI. An electrocardiogram (ECG) transmission system is adopted to confirm the STEMI diagnosis. Since the hospital provide a 24/7 service, most of the STEMI cases were transferred to the national cardiovascular
hospital, particularly during off-hours. A pre-hospital triage form was developed to improve the acute phase management [19].

The reporting of this study was in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline [31]. This study has been approved by the local Institutional Review Board (IRB) (No. LB.02.01/VII/233?KEP.004/2018).

2.2. Patients and exposure

A total number of 2694 patients with STEMI were recorded. Of these, 1132 patients (42%) did not receive acute reperfusion therapy and were included in the final analysis. The majority (74.9%) of the non-reperfused patients were late presenters, defined as presenting >12 h from symptoms of STEMI [25]. Diagnosis of STEMI was made based on the presence of typical chest pain and ST-segment elevation (≥0.1 mV) in two or more contiguous leads on the initial ECG [16, 17, 19]. Acute reperfusion therapy was defined as pPCI or fibrinolytic therapy. Of 1562 patients who received acute reperfusion therapy, 91% were treated with pPCI.

 Patients were divided into two groups: guideline-adherent group and guideline non-adherent group. We used the American College Cardiology (ACC)/American Heart Association (AHA) and European Society of Cardiology (ESC) guidelines for the management of patients with STEMI as these were adopted by the Indonesian guideline [9, 32, 33]. Adherence to guideline-recommended medications for each patient was defined as receiving a combination of all four medications (aspirin, clopidogrel, parenteral anticoagulants and statins) after hospital admission. Clinicians assured that all patients received their medications during the hospital stay. Patients who received the combination of all four medications were included into the guideline-adherent group. Patients who received less than four of these medications, i.e. 0–3 of the recommended medications were included into the guideline non-adherent group.

2.3. Outcomes, follow-up and potential confounders

The primary outcome was in-hospital mortality as recorded in the registry. Patients were followed-up from the date of admission to the date of death in hospital, discharge from the hospital, or the end of the study period. Potential confounders were patient’s characteristics considered to be associated with the use of at least one type of the in-hospital preventive medications or in-hospital mortality found in previous studies in patients with acute MI and ACS [20, 27–30, 34, 35]. Only one study, observing patients with ACS, reported a clear association between several patient’s characteristics (type of MI, cardiac enzyme, and Killip class) and the optimal use of these medications [35].

Based on the completeness of variables observed in the registry (missing observation less than 5%), the following variables were selected as potential confounders in our study: age (categorized into ≤65 or >65 years), sex, family history of coronary artery disease (CAD), hypertension, diabetes, dyslipidemia, smoking status, Killip class (1 or >1), onset of STEMI (≤12 or >12 h), anterior MI, Thrombolysis in Myocardial Infarction (TIMI) score (<4 or ≥4), and other cardiovascular-preventive medications administered after hospital admission.

2.4. Statistical analysis

The data on categorical variables were presented as proportions. All comparisons in variable distributions between groups were tested using $\chi^2$-test for each variable. A binary logistic regression model was used to estimate the crude association between exposure status and in-hospital mortality, and was presented as an odds ratio (OR) with 95% confidence interval (CI). We applied multivariable logistic regression analysis to obtain an adjusted OR by including significant potential confounders from the univariable analysis.

All statistical analysis to test the difference of variable distribution between groups were two-sided and $p < 0.05$ were considered significant. All analyses were performed using the Statistical Package for the Social Sciences, V21 (SPSS 21).

3. Results

Out of total 1132 non-reperfused STEMI patients, the majority (81.4%) were middle-aged (<65 years), males (85.1%) and referred from other hospitals (52.9%). The three most common IHD risk factors identified were smoking (62.8%), hypertension (51.3%) and diabetes (32.2%). The majority of patients had an anterior MI (61.7%).

There were 778 patients (68.7%) in the guideline-adherent group and 354 patients (31.3%) in the guideline non-adherent group (Figure 1). There were more patients with family history of CAD, hypertension, and smoking habit in the guideline-adherent group compared to those in the guideline non-adherent group, although the differences were not statistically significant.
Three key significant variables correlated with non-adherence were all indicators of a more severe/acute STEMI: higher TIMI score (≥4), higher Killip class (>1), and more recent onset of STEMI (≤12h). The guideline non-adherent group were also less likely to receive angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs) within 24 h after hospitalization compared to the guideline adherent group (Table 1).

All included patients had a complete follow-up. Overall, in-hospital mortality of non-reperfused STEMI patients within the period of observation was 12.2%. As expected, the non-surviving group had significantly more patients with Killip class >1 and TIMI score ≥4 and less patients treated with ACEIs/ARBs within 24 h (Table 2).

In univariable analysis, guideline-adherence in non-reperfused STEMI patients was associated with lower odds of in-hospital mortality (OR: 0.32, 95% CI 0.22–0.46) (Table 3). After adjustment for potential founders (onset of STEMI, Killip class, TIMI score, and administration of ACEIs/ARBs within 24 h after hospitalization), the adjusted OR was 0.46 (95% CI 0.30–0.70). When the association between guideline-adherence and in-hospital mortality was analysed in multivariable analysis that also adjusted for other potential confounders (age, sex, family history of CAD, hypertension, dyslipidaemia, diabetes, smoking status, anterior MI, onset of STEMI, Killip class, TIMI score, and ACEIs/ARBs administration), the result did not change (adjusted OR: 0.46, 95% CI 0.30–0.70).

4. Discussion

Almost 70% of non-reperfused STEMI patients received all four medications (DAPT [aspirin and clopidogrel], anticoagulants, and statins) as recommended by guidelines. This level of adherence was significantly associated with a 54% reduction in the odds of in-hospital mortality after adjusting for potential confounders. It seems that the acuteness and severity of patients admitted with STEMI correlated positively with guideline non-adherence.

4.1. Comparison with other studies

Most previous studies observed guideline adherence of preventive medications administered at discharge [36, 37]. Two slightly similar studies looked at a different set of medications in patients with ACS in Vietnam [20] and India [35]. In Vietnam, guideline adherence was defined as prescribing DAPT, beta blockers, ACEIs/ARBs, and statins both within 24 h after hospital admission and at-discharge [20], while in India, it was defined as receiving DAPT, heparin, beta blockers, and statins in hospital only [35]. The proportion of STEMI patients in both studies was under 40% with unclear report on the number of non-reperfused patients. However, pPCI was only received by 25% and 12% of ACS patients in both studies respectively, suggesting substantial patients with STEMI were not reperfused. The level of guideline-adherence in both studies were lower than our study, 46% in Vietnam and 40% in India [20, 35]. This difference is probably due to the difference of population understudied and the definition of guideline adherence. Due to incompleteness of some clinical data, we observed less types of medication to avoid misclassification of adherence.
The trend of higher risk patients (indicated by a higher Killip class and TIMI score) not receiving guideline-recommended preventive medications is comparable with the Indian study. Killip class >1 and positive cardiac enzyme significantly predicted sub-optimal in-hospital preventive medications in Indian ACS patients [35]. A phenomenon of higher risk patients less likely receiving guideline-recommended treatment compared to lower risk patients, known as a treatment-risk paradox, has been investigated in patients with NSTEMI [36, 38, 39]. The causes of this paradox have not been adequately studied. The tendency of physicians to avoid invasive intervention in patients perceived to be at higher risk of procedure-related complications, such as bleeding or stroke, has been suggested to partly cause this paradox in NSTEMI patients [38]. A study on predictors of not receiving secondary preventive medications at-discharge in patients with STEMI found chronic oral anticoagulation and in-hospital bleeding as two important predictors of not receiving aspirin or clopidogrel [40]. Since the level of adherence in the use of anticoagulants alone was the lowest compared to the others in our study, thus contributes to the overall level of adherence, we suggested some conditions that would increase a perceived potential adverse effect or complication might discourage the administration of triple antithrombotic medications in higher risk or sicker patients, e.g. higher risk of

| Table 1: Baseline characteristics of patients with ST-segment elevation myocardial infarction not receiving acute reperfusion therapy. |
| Patient's characteristicsa | Guideline-adherent (N = 778) | Guideline non-adherent (N = 354) | p-valueb | Missing observation (% of total N) |
|----------------------------|-----------------------------|---------------------------------|----------|----------------------------------|
| Age > 65 years, n (%)      | 144 (18.5)                  | 67 (18.9)                       | 0.867    | 0                                 |
| Males, n (%)               | 669 (86.0)                  | 294 (83.1)                      | 0.198    | 0                                 |
| Source of referral, n (%)  |                             |                                 |          |                                   |
| Inter-hospital             | 399 (51.2)                  | 200 (56.5)                      | 0.437    | 0                                 |
| Walk in/ambulance          | 335 (43.1)                  | 137 (38.7)                      |          |                                   |
| Intra-hospital             | 30 (3.9)                    | 12 (3.4)                        |          |                                   |
| Primary physician          | 14 (1.8)                    | 5 (1.4)                         |          |                                   |
| IHD risk factors, n (%)    |                             |                                 |          |                                   |
| Family history of CAD      | 134 (17.2)                  | 48 (13.6)                       | 0.120    | 0                                 |
| Hypertension               | 406 (52.2)                  | 175 (49.4)                      | 0.391    | 0                                 |
| Diabetes                   | 250 (32.1)                  | 114 (33.2)                      | 0.981    | 0                                 |
| Dyslipidemia               | 227 (29.2)                  | 99 (28.0)                       | 0.677    | 0                                 |
| Smokers                    | 499 (64.1)                  | 212 (59.9)                      | 0.170    | 0                                 |
| Hospital findings, n (%)   |                             |                                 |          |                                   |
| Onset of STEMI ≤ 12 h      | 161 (20.8)                  | 113 (32.4)                      | <0.0005  | 10 (0.9)                         |
| Anterior MI                | 480 (61.9)                  | 219 (62.4)                      | 0.863    | 5 (0.4)                          |
| Killip class > 1           | 270 (35.1)                  | 158 (46.7)                      | <0.0005  | 25 (2.2)                         |
| TIMI score ≥ 4             | 367 (48.3)                  | 177 (55.8)                      | 0.024    | 55 (4.9)                         |
| Random blood glucose ≥ 200 mg/dL | 198 (25.8) | 97 (29.4)                      | 0.220    | 35 (3.1)                         |
| Other medications administered after admission, n (%) |   |   |   |                                   |
| GP IIb/IIa inhibitors      | 11 (1.4)                    | 5 (1.4)                         | 0.998    | 0                                 |
| Beta blockers              | 214 (27.5)                  | 96 (27.3)                       | 0.935    | 2 (0.2)                          |
| ACEIs/ARBs                 | 421 (54.1)                  | 167 (47.4)                      | 0.038    | 2 (0.2)                          |

a Percentage was calculated as the number of patients with a certain characteristic per total number in each group excluding any missing observations.

b χ² test, bold type indicated statistical significance.

ACEIs = angiotensin-converting enzyme inhibitors, ARBs = angiotensin receptor blockers, CAD = coronary artery disease, GP = glycoprotein, h = hour, IHD = ischemic heart disease, MI = myocardial infarction, STEMI = ST-segment elevation myocardial infarction, TIMI = thrombolysis in myocardial infarction.
bleeding, oral anticoagulant co-medications. We also can not rule out patient’s factors such as refusal of receiving medications due to personal reasons.

Moreover, the management of STEMI is not guided by a risk stratification as in NSTEMI [32, 33]. It is assumed that similar treatment will be beneficial for all patients with STEMI, even more in the non-reperfused ones. However, evidence used to support this suggestion is based on patients with lower risk of in-hospital mortality compared to ‘real-world’ setting [28–30]. Thus, there is still a gap of knowledge on the benefit of secondary preventive medications in this subpopulation, especially when the perceived potential adverse effects might counterbalance the benefits in higher risk patients and when there is no clear stratification of risk in this population.

While optimal use of in-hospital medications showed a non-statistical significant trend towards lower in-hospital mortality in Indian patients with ACS [35], our study found otherwise. Different types of medications being assessed and population understudied likely contribute to different results. A recent observational study investigated an association between UFH or enoxaparin and in-hospital mortality in non-reperfused STEMI patients who the majority also received aspirin (95%) and clopidogrel (71%). Information on the use of other preventive medications including statins was not reported. In the subgroup analysis, the use of UFH was associated with a lower risk of the odds of in-hospital mortality in clopidogrel users only (OR: 0.62, 95% CI 0.41–0.94) while this effect was not significant in clopidogrel non-users. The higher protective effect of a combined medication shown in our study suggests that an early use of statins (within 24-h after hospital admission) might contribute to further reduction in in-hospital mortality. Nevertheless, little is known on pharmacological mechanism of statins in concert with DAPT and anticoagulants in late presenter non-reperfused STEMI patients who has a higher prothrombotic state as a specific pathophysiological condition [27].

**Table 2:** Distribution of potential confounders between non-reperfused STEMI patients who were alive and deceased during hospitalization.

| Potential confounders | Deceased (N = 138) | Alive (N = 994) | p-valueb | Missing observation (% of total N) |
|-----------------------|--------------------|----------------|----------|----------------------------------|
| Hospital findings, n (%) |                    |                |          |                                  |
| Onset of STEMI ≤12 h | 46 (34.1)          | 228 (23.1)     | 0.005    | 10 (0.9)                         |
| Killip class >1      | 95 (72.5)          | 333 (34.1)     | <0.0005  | 25 (2.2)                         |
| TIMI score ≥4        | 98 (81.7)          | 446 (46.6)     | <0.0005  | 55 (4.9)                         |

| Medications administered after admission, n (%) | |
|-----------------------------------------------|-----------------------------|
| ACEIs/ARBs | 39 (28.5) | 549 (55.3) | <0.0005 | 2 (0.2) |

* Percentage was calculated as the number of patients with a certain characteristic per total number in each group excluding missing observation.

χ² test, bold type indicated statistical significance.

ACEIs = angiotensin-converting enzyme inhibitors, ARBs = angiotensin receptor blockers, h = hour, STEMI = ST-segment elevation myocardial infarction, TIMI = thrombolysis in myocardial infarction.

**Table 3:** Association between adherence to guideline-recommended medications and in-hospital mortality in non-reperfused STEMI patients.

| In-hospital mortality | Crude OR (95% CI) | Adjusted OR (95% CI)b |
|-----------------------|-------------------|-----------------------|
| N of death/total (%)  |                   |                       |
| Guideline-adherentb   | 62/778 (8.0)      | 0.32 (0.22–0.46)      | 0.46 (0.30–0.70) |
| Guideline non-adherentc | 76/354 (21.5)    |                       |

* Adjusted for onset of STEMI, Killip class, TIMI score and administration of ACEIs/ARBs.

b Guideline-adherent was defined as receiving a combination of all four medications (aspirin, clopidogrel, anticoagulant and statins).

c Guideline non-adherent was defined as receiving less than four medications.

ACEIs = angiotensin-converting enzyme inhibitors, ARBs = angiotensin receptor blockers, CI = confidence interval, OR = odds ratio, STEMI = ST-segment elevation myocardial infarction, TIMI = thrombolysis in myocardial infarction.
4.2. Limitations

Several limitations should be acknowledged when interpreting the result of this study. First, since we only measured the level of adherence to the medications at hospital admission (mostly within 24 h) and did not directly observe patients taking the medications during hospitalization, this may have led to some misclassification of exposure. However, as the hospital is JCI accredited, this process was monitored daily by nurses and pharmacists and therefore should not have resulted in a large bias.

Secondly, since the OR is a statistic output of the logistic regression and the outcome rate was not rare (>10% in non-exposed group) the OR most likely will overestimate the true relative risk (RR). After correction of the adjusted OR using formula developed by Zhang and Yu [41, 42], the adjusted RR was 0.52 (95% CI 0.35–0.75) which is still highly significant.

Thirdly, we could not assess conditions that contraindicated the use of DAPT, anticoagulants, and statins, such as history of intolerance, active gastrointestinal bleeding, or active liver disease [20, 43–46]. The prevalence of conditions that contraindicated the use of these medications in STEMI patients has also rarely been reported in previous studies. In one study, all patients with STEMI were eligible for receiving aspirin/clopidogrel and only 0.9% were not eligible for receiving statins [43]. Consequently, although we cannot exactly know the effect of contra-indications on in-hospital mortality, this might overestimate the level of guideline adherence.

Finally, although the association between guideline-adherence and in-hospital mortality has been adjusted for potential confounders, the possibility of confounding by other unmeasured potential confounders, such as prior CVD (MI, stroke), medications or treatment used prior to hospital admission, lipid profile, baseline systolic blood pressure (SBP), left ventricular ejection fraction (LVEF) profile, body mass index (BMI), and other comorbidities (asthma/chronic obstructive pulmonary disease [COPD]; renal dysfunction; heart failure) or healthy lifestyle, may have biased our finding away from the null.

4.3. Future directions

Our findings should reinforce the use of guideline recommended secondary preventive medications in non-reperfused STEMI patients. The indication of treatment-risk paradox that may challenge the adherence to guideline recommended preventive medications in this subpopulation is intriguing. Several strategies to minimize this paradox, such as reimbursement (pay for performance incentives), modifying the practice setting (e.g. practice aids), and multidisciplinary approach, has been proposed in the management of NSTEMI patients [39]. However, due to the difference in management between STEMI and NSTEMI, the causes of this paradox may not be the same. The presence of this paradox needs to be confirmed to identify a more appropriate strategy. The predictors of not receiving medications in this subpopulation need to be identified in future research.

5. Conclusions

Approximately two-thirds of non-reperfused STEMI patients admitted to a tertiary academic hospital in Indonesia, a developing country, received in-hospital preventive medications according to international guidelines. This level of adherence has contributed to reduction of the odds of in-hospital mortality by 54%. The predictors of not receiving these preventive medications need to be further investigated.

Competing Interests

The authors have no competing interests to declare.

Funding Information

Sylvi Irawati received support for research from the Indonesia Endowment Fund for Education (Lembaga Pengelola Dana Pendidikan, LPDP), the Ministry of Finance of the Republic of Indonesia, in the form of scholarship for her PhD program. LPDP had no role in research design, data collection, analysis and interpretation, or manuscript writing and publication.

Author Contributions

SI, SD, KT, TN, BW, EH contributed to the study design, drafting, interpretation, review and final approval of the manuscript. Authors SI and NN contributed to the statistical analysis of the data. Authors SD and NN had full access to all of the data used in the study.
References

1. **GBD 2013 Mortality and Causes of Death Collaborators.** Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet.* 2015; 385(9963): 117–71. DOI: https://doi.org/10.1016/S0140-6736(14)61682-2

2. **The World Bank Group.** World Bank analytical classifications (presented in World Development Indicators). 2015. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519 (accessed 20 June 2018).

3. **Richmond Vale Academy.** List of developing countries in 2016. 2018 http://richmondvale.org/developing-countries-list/ (accessed 19 June 2018).

4. **GBD 2015 Mortality and Causes of Death Collaborators.** Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet.* 2016; 388(10053): 1459–544. DOI: https://doi.org/10.1016/S0140-6736(16)31012-1

5. **World Health Organization.** Global health estimates 2015: deaths by cause, age, sex, by country and by region, 2000–2015. 2016 http://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html (accessed 20 June 2018).

6. **Martinez R, Soliz P, Caixeta R,** et al. Reflection on modern methods: years of life lost due to premature mortality: a versatile and comprehensive measure for monitoring non-communicable disease mortality. *Int J Epidemiol.* 2019; 48(4): 1367–76. DOI: https://doi.org/10.1093/ije/dyy254

7. **Sanchis-Gomar F, Perez-Quilis C, Leischik R,** et al. Epidemiology of coronary heart disease and acute coronary syndrome. *Ann Transl Med.* 2016; 4(13): 256. DOI: https://doi.org/10.21037/atm.2016.06.33

8. **Amsterdam EA, Wenger NK, Brindis RG,** et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2014; 64(24): e139–228.

9. **O’Gara PT, Kushner FG, Ascheim DD,** et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2013; 61(4): 78–140. DOI: https://doi.org/10.1016/j.jacc.2012.11.019

10. **Roffi M, Patrono C, Collet J-P,** et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J.* 2016; 37(3): 267–315. DOI: https://doi.org/10.1093/eurheartj/ehv320

11. **Ibanez B, James S, Agewall S,** et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J.* 2017; 00: 1–66. DOI: https://doi.org/10.1016/j.ehjrec.2017.11.010

12. **Moran AE, Forouzanfar MH, Roth GA,** et al. The global burden of ischemic heart disease in 1990 and 2010: the global burden of disease 2010 study. *Circulation.* 2014; 129(14): 1493–501. DOI: https://doi.org/10.1161/CIRCULATIONAHA.113.004046

13. **Fox KAA, Dabbous OH, Goldberg RJ,** et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). *BMJ.* 2006; 333(7578): 1091. DOI: https://doi.org/10.1136/bmj.38985.646481.55

14. **Dasari TW, Hamilton S, Chen AY,** et al. Non-eligibility for reperfusion therapy in patients presenting with ST-segment elevation myocardial infarction: contemporary insights from the National Cardiovascular Data Registry (NCDR). *Am Heart J.* 2016; 172: 1–8. DOI: https://doi.org/10.1016/j.ahj.2015.10.014

15. **Huo Y, Thompson P, Buddhari W,** et al. Challenges and solutions in medically managed ACS in the Asia-Pacific region: expert recommendations from the Asia-Pacific ACS Medical Management Working Group. *Int J Cardiol.* 2015; 183(2015): 63–75. DOI: https://doi.org/10.1016/j.ijcard.2014.11.195

16. **Dharma S, Juzar DA, Firdaus I,** et al. Acute myocardial infarction system of care in the third world. *Neth Heart J.* 2012; 20(6): 254–9. DOI: https://doi.org/10.1007/s12471-012-0259-9

17. **Dharma S, Andrianrora H, Dakota I,** et al. Organisation of reperfusion therapy for STEMI in a developing country. *Open Heart.* 2015; 2(1): e000240. DOI: https://doi.org/10.1136/openhrt-2015-000240
18. Dharma S, Andriantoro H, Purnawan I, et al. Characteristics, treatment, and in-hospital outcomes of patients with STEMI in a metropolitan area of a developing country: an initial report of the extended Jakarta Acute Coronary Syndrome registry. *BMJ Open*. 2016; 6(8): e012193. DOI: https://doi.org/10.1136/bmjopen-2016-012193corr1

19. Dharma S, Siswanto BB, Firdaus I, et al. Temporal trends of system of care for STEMIs: Insights from the Jakarta Cardiovascular Care Unit Network system. *PLoS One*. 2014; 9(2): 1–5. DOI: https://doi.org/10.1371/journal.pone.0086665

20. Nguyen T, Le KK, Cao HTK, et al. Association between in-hospital guideline adherence and postdischarge major adverse outcomes of patients with acute coronary syndrome in Vietnam: a prospective cohort study. *BMJ Open*. 2017; 7(10): e017008. DOI: https://doi.org/10.1136/bmjopen-2017-017008

21. Alter DA, Ko DT, Newman A, et al. Factors attributed to the higher in-hospital mortality of ST elevation myocardial infarction. *Eur Hear J*. 2006; 27(13): 1539–49. DOI: https://doi.org/10.1093/eurheartj/ehl066

22. Fox KAA, Eagle KA, Gore JM, et al. The global registry of acute coronary events, 1999 to 2009-GRACE. *Heart*. 2010; 96(14): 1095–101. DOI: https://doi.org/10.1136/hrt.2009.190827

23. Kristensen SD, Laut KG, Fajadet J, et al. Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. *Eur Hear J*. 2014; 35(29): 1957–70. DOI: https://doi.org/10.1093/eurheartj/ehp1529

24. Schömig A, Mehilli J, Antoniucci D, et al. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. *JAMA*. 2005; 293(23): 2865–72. DOI: https://doi.org/10.1001/jama.293.23.2865

25. Cohen M, Boiangiu C, Abidi M. Therapy for ST-segment elevation myocardial infarction patients who present late or are ineligible for reperfusion therapy. *J Am Coll Cardiol*. 2010; 55(18): 1895–906. DOI: https://doi.org/10.1016/j.jacc.2009.11.087

26. Gierlotka M, Gasior M, Wilczek K, et al. Reperfusion by primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction within 12 to 24 hours of the onset of symptoms (from a Prospective National Observational Study [PL-ACS]). *Am J Cardiol*. 2011; 107(4): 501–8. DOI: https://doi.org/10.1016/j.amjcard.2010.02.008

27. Bugiardini R, Dorobantu M, Vasiljevic Z, et al. Unfractionated heparin-clopidogrel combination in ST-elevation myocardial infarction not receiving reperfusion therapy. *Atherosclerosis*. 2015; 241: 151–6. DOI: https://doi.org/10.1016/j.atherosclerosis.2015.04.794

28. COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. *Lancet*. 2005; 366: 1607–21. DOI: https://doi.org/10.1016/S0140-6736(05)67660-X

29. Oldgren J, Wallentin L, Afzal R, et al. Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. *Eur Hear J*. 2008; 29(3): 315–23. DOI: https://doi.org/10.1093/eurheartj/ehm578

30. Cohen M, Gensini GF, Maritz F, et al. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. *J Am Coll Cardiol*. 2003; 42(8): 1348–56. DOI: https://doi.org/10.1016/S0735-1097(03)01040-4

31. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. *PLoS Med*. 2007; 4(10): 1628–54. DOI: https://doi.org/10.1371/journal.pmed.0040297

32. Indonesian Heart Association. Pedoman tatalaksana sindrom koroner akut. 2015. http://www.inaheart.org/upload/file/Pedoman_Tatalaksana_Sindrom_Koroner_Akut_2015.pdf (accessed 13 Nov 2017).

33. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Hear J*. 2012; 33(20): 2569–619. DOI: https://doi.org/10.1093/eurheartj/ehs215

34. Li M, Li S, Du X, et al. Factors attributed to the higher in-hospital mortality of ST elevation myocardial infarction patients admitted during off-hour in comparison with those during regular hour. *PLoS One [Internet]*. 2017; 12(4): e0175485. DOI: https://doi.org/10.1371/journal.pone.0175485
35. Huffman MD, Prabhakaran D, Abraham A, et al. Optimal in-hospital and discharge medical therapy in acute coronary syndromes in Kerala: Results from the Kerala ACS Registry. *Circ Cardiovasc Qual Outcomes*. 2013; 6(4): 436–43. DOI: https://doi.org/10.1161/CIRCOUTCOMES.113.000189

36. Hall M, Bebb OJ, Dondo TB, et al. Guideline-indicated treatments and diagnostics, GRACE risk score, and survival for non-ST elevation myocardial infarction. *Eur Heart J*. 2018; 39(42): 3798–806. DOI: https://doi.org/10.1093/eurheartj/ehy517

37. Tomasevic D, El Khoury C, Subtil F, et al. Effect of optimal medical therapy at discharge in patients with reperfused ST-segment elevation myocardial infarction on 1-year mortality (from the Regional RESCUe Registry). *Am J Cardiol*. 2018; 121(4): 403–9. DOI: https://doi.org/10.1016/j.amjcard.2017.11.002

38. Saar A, Marandi T, Ainla T, et al. The risk-treatment paradox in non-ST-elevation myocardial infarction patients according to their estimated GRACE risk. *Int J Cardiol*. 2018; 272: 26–32. DOI: https://doi.org/10.1016/j.ijcard.2018.08.015

39. Roffi M, Mukherjee D. Treatment-risk paradox in acute coronary syndromes. *Eur Heart J*. 2018; 39(42): 3807–9. DOI: https://doi.org/10.1093/eurheartj/ehy577

40. Bauer T, Gitt AK, Jünger C, et al. Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence. *Eur J Cardiovasc Prev Rehabil*. 2010; 17(5): 576–81. DOI: https://doi.org/10.1097/HJR.0b013e328338e5da

41. Sainani KL. Understanding odds ratios. *PM&R*. 2011; 3(3): 263–7. DOI: https://doi.org/10.1016/j.pmrj.2011.01.009

42. Zhang J, Yun KF. What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. *JAMA*. 1998; 280(19): 1690–1. DOI: https://doi.org/10.1001/jama.1998.01690

43. Schiele F, Meneveau N, Seronde MF, et al. Compliance with guidelines and 1-year mortality in patients with acute myocardial infarction: A prospective study. *Eur Heart J*. 2005; 26(9): 873–80. DOI: https://doi.org/10.1093/eurheartj/ehi107

44. Nguyen T, Nguyen TH, Pham HTK, et al. Physicians’ adherence to acute coronary syndrome prescribing guidelines in Vietnamese hospital practice: a cross-sectional study. *Trop Med Int Health*. 2015; 20(5): 627–37. DOI: https://doi.org/10.1111/tmi.12467

45. Mehta SR, Bassand J, Chrolavicius S, et al. Design and rationale of CURRENT-OASIS 7: a randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. *Am Heart J*. 2018; 156(6): 1080–88.e1. DOI: https://doi.org/10.1016/j.ahj.2008.07.026

46. Wang Y, Fu R, Wang Z, et al. Assessing the quality of care for patients with acute myocardial infarction in China. *Clin Cardiol*. 2015; 38(6): 327–32. DOI: https://doi.org/10.1002/clc.22405

How to cite this article: Irawati S, Dharma S, Taxis K, Nguyen T, Nursyarofah N, Wilffert B, Hak E. Association between Adherence to Guideline-Recommended Preventive Medications and In-Hospital Mortality among Non-Reperfused ST-Elevation Myocardial Infarction Patients Admitted to a Tertiary Care Academic Center in a Developing Country. *Global Heart*. 2020; 15(1): 8. DOI: https://doi.org/10.5334/gh.394

Submitted: 27 June 2019 Accepted: 23 October 2019 Published: 06 February 2020

Copyright: © 2020 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/.